BerGenBio and Oncoinvent Merge to Advance Cancer Treatments
BerGenBio ASA and Oncoinvent ASA have officially announced a merger agreement that aims to bring together their strengths in the fight against cancer. This partnership is expected to significantly enhance the clinical strategies of both companies, primarily focusing on the development of groundbreaking therapies for patients suffering from cancers in the abdominal cavity.
The Merger Details
As part of the merger, BerGenBio will acquire Oncoinvent in a statutory merger. This strategic move allows BerGenBio to leverage its resources to streamline Oncoinvent's capabilities, ultimately promoting the development of innovative treatments that could change the lives of cancer patients.
Key Benefits of the Merger
One of the major advantages this merger brings is the combined capital and operational resources, which will support Oncoinvent's clinical development plan significantly. The exchange ratio set for this merger is 25% for BerGenBio and 75% for Oncoinvent. This moots an impressive valuation for BerGenBio and opens doors for liquidity and funding for further research and development.
After the merger completes, the new entity will conduct a fully underwritten rights issue. Proceeds from this initiative are anticipated to provide ample financial support for Oncoinvent's clinical programs well into the future.
Supporting Statements from Leadership
Anders Tullgren, chair of the board of BerGenBio, expressed his optimism about the merger, noting that it provides current shareholders with an exciting opportunity to be part of a progressive company utilizing innovative radiopharmaceutical technology which has shown promising initial efficacy results.
Oncoinvent’s CEO, Øystein Soug, looks forward to the strengthened financial position that this merger will bestow upon the company. He emphasizes that with better resources, Oncoinvent can enhance its focused strategy to evolve Radspherin® in the treatment of ovarian cancer.
About Oncoinvent and Its Innovations
Oncoinvent is recognized for its cutting-edge work in the field of radiopharmaceutical therapies. Their flagship product candidate, Radspherin®, is designed to target micro-metastases following surgical procedures. The ongoing clinical trials, including phase 1 and phase 2 studies, have shown very encouraging data without significant safety concerns. The merger is poised to accelerate these promising research endeavors.
Exciting Prospects for the Future
The union between BerGenBio and Oncoinvent is expected to broaden the shareholder base and improve overall liquidity. Not only does this strengthen their market position, but it also prepares the merged entity for compliance with regulatory bodies like the Oslo Stock Exchange for potential uplisting.
Road Ahead
As both companies complete the preliminary steps toward finalizing the merger, stakeholder meetings are on the horizon. The combined entity's future strategy will center on enhancing cancer treatment options and ensuring that its portfolio reaches the patients who need it most.
Frequently Asked Questions
What is the primary focus of the merger between BerGenBio and Oncoinvent?
The merger aims to combine their strengths to enhance clinical strategies targeting effective cancer therapies, particularly for abdominal cavity cancers.
What benefits will the merger provide for shareholders?
Shareholders will benefit from potential value increase through broader market access and increased liquidity.
How will the merger impact Oncoinvent's clinical development?
The merger will provide significant financial resources to support ongoing clinical trials and potentially speed up the development of innovative therapies.
What is the future plan for the merged company?
The merged entity plans to focus on enhancing shareholder value, improving liquidity, and advancing clinical strategies for cancer treatments.
When is the anticipated completion date for the merger?
All conditions for the merger are expected to be satisfied by mid-September 2025, barring any unforeseen delays.
